Two decades of medical innovation in lung cancer care have failed to eliminate racial treatment disparities, suggesting systemic barriers beyond technology may drive unequal outcomes. Despite the introduction of stereotactic body radiotherapy (SBRT) as a standard treatment option and other therapeutic advances, Black Medicare beneficiaries continue receiving curative treatment at markedly lower rates than their White counterparts.
Analyzing 28,287 patients diagnosed with early-stage non-small cell lung cancer across three time periods from 2005 to 2019, researchers documented persistent treatment gaps between Black and White patients aged 66 to 85 years. The study tracked receipt of curative interventions including surgery and radiotherapy, with particular attention to preferred modalities like lobectomy and SBRT. Historical data from the 1990s and early 2000s had shown 13-15% disparities in curative therapy access, providing a baseline for measuring progress.
This persistence of racial disparities despite technological improvements reveals that access barriers extend beyond treatment availability. The findings challenge assumptions that medical advances automatically translate to equitable care delivery. While SBRT represented a significant advancement by offering effective treatment for patients unable to undergo surgery, its integration into clinical practice has not eliminated racial gaps in care quality. The research underscores how healthcare disparities can persist even when new treatment options emerge, pointing to deeper structural issues within cancer care delivery systems. For health-conscious adults, particularly those approaching Medicare eligibility, these findings highlight the importance of proactive healthcare advocacy and the ongoing need for systemic reform in oncology care access.